Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy

Published:2022-05-10 Issue:1 Volume:54 Page:1339-1349
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Minichsdorfer Christoph¹,Gleiss Andreas²,Aretin Marie-Bernadette³,Schmidinger Manuela⁴,Fuereder Thorsten¹

Affiliation:

1. Department of Medicine I & CCC, Division of Oncology, Medical University of Vienna, Wien, Austria

2. Medical University of Vienna, Center for Medical Statistics, Informatics, and Intelligent Systems Institute of Clinical Biometrics, Wien, Austria

3. Pharmacy Department, Vienna General Hospital – Medical University Campus, Wien, Austria

4. Department of Urology, Medical University of Vienna, Wien, Austria

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2022.2070660

Reference46 articles.

1. Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation

2. Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

3. Pembrolizumab in classical Hodgkin's lymphoma

4. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

5. HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study;Cancer Investigation;2024-07-02

2. C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy;Scientific Reports;2024-06-14

3. Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab;Journal of Clinical Medicine;2024-04-23

4. Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer;BMC Cancer;2024-04-08

5. Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?;Cancers;2024-01-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3